Combination treatment with metronomic temozolomide, bevacizumab and long-acting octreotide for malignant neuroendocrine tumours

被引：44

作者：

Koumarianou, Anna ^{[1
]}

Antoniou, Stavroula ^{[2
]}

Kanakis, George ^{[2
]}

Economopoulos, Nikolaos ^{[3
]}

Rontogianni, Dimitra ^{[4
]}

Ntavatzikos, Anastasios ^{[5
]}

Tsavaris, Nikolaos ^{[6
]}

Pectasides, Dimitrios ^{[1
]}

Dimitriadis, George ^{[1
]}

Kaltsas, Gregory ^{[2
]}

机构：

[1] Attikon Univ Gen Hosp, Dept Internal Med Propaedeut 2, Med Oncol Unit, Athens 12462, Greece

[2] Natl Univ Athens, Laiko Univ Hosp, Dept Pathophysiol, Endocrine Unit, Athens 11527, Greece

[3] Attikon Univ Gen Hosp, Dept Radiol, MRI Unit, Athens 12462, Greece

[4] Natl Univ Athens, Pathol Dept Evangelismos Hosp, Athens 11527, Greece

[5] Natl Univ Athens, Dept Surg 4, Attikon Univ Hosp, Athens 11527, Greece

[6] Natl Univ Athens, Dept Pathophysiol, Med Oncol Unit, Laiko Univ Hosp, Athens 11527, Greece

来源：

关键词：

PHASE-II; CHEMOTHERAPY; SCHEDULES; GROWTH;

D O I：

10.1530/ERC-11-0287

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：L1 / L4

页数：4

共 15 条

[1]

[Anonymous], 2010, WHO Classification of tumors of the digestive system

[2] New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].

Eisenhauer, E. A. ;

Therasse, P. ;

Bogaerts, J. ;

Schwartz, L. H. ;

Sargent, D. ;

Ford, R. ;

Dancey, J. ;

Arbuck, S. ;

Gwyther, S. ;

Mooney, M. ;

Rubinstein, L. ;

Shankar, L. ;

Dodd, L. ;

Kaplan, R. ;

Lacombe, D. ;

Verweij, J. .

EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247

[3] Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors [J].

Ekeblad, Sara ;

Sundin, Anders ;

Janson, Eva Tiensuu ;

Welin, Staffan ;

Granberg, Dan ;

Kindmark, Henrik ;

Dunder, Kristina ;

Kozlovacki, Gordana ;

Orlefors, Hakan ;

Sigurd, Mattias ;

Oberg, Kjell ;

Eriksson, Barbro ;

Skogseid, Britt .

CLINICAL CANCER RESEARCH, 2007, 13 (10) :2986-2991

[4] Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms [J].

Grozinsky-Glasberg, Simona ;

Shimon, Ilan ;

Korbonits, Marta ;

Grossman, Ashley B. .

[5]

Kulke M, 2010, 2010 ASCO GAST CANC

[6]

Kulke MH, 2006, J CLIN ONCOL, V24, p189S

[7] Future Directions in the Treatment of Neuroendocrine Tumors: Consensus Report of the National Cancer Institute Neuroendocrine Tumor Clinical Trials Planning Meeting [J].

Kulke, Matthew H. ;

Siu, Lillian L. ;

Tepper, Joel E. ;

Fisher, George ;

Jaffe, Deborah ;

Haller, Daniel G. ;

Ellis, Lee M. ;

Benedetti, Jacqueline K. ;

Bergsland, Emily K. ;

Hobday, Timothy J. ;

Van Cutsem, Eric ;

Pingpank, James ;

Oberg, Kjell ;

Cohen, Steven J. ;

Posner, Mitchell C. ;

Yao, James C. .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07) :934-943

[8] Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors [J].

Kulke, MH ;

Stuart, K ;

Enzinger, PC ;

Ryan, DP ;

Clark, JW ;

Muzikansky, A ;

Vincitore, M ;

Michelini, A ;

Fuchs, CS .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (03) :401-406

[9] Metronomic chemotherapy dosing-schedules with estramustine and temozolomide act synergistically with anti-VEGFR-2 antibody to cause inhibition of human umbilical venous endothelial cell growth [J].

Lam, Thomas ;

Hetherington, John W. ;

Greenman, John ;

Little, Samantha ;

Maraveyas, Anthony .

ACTA ONCOLOGICA, 2007, 46 (08) :1169-1177

[10] Gastroenteropancreatic neuroendocrine tumours [J].

Modlin, Irvin M. ;

Oberg, Kjell ;

Chung, Daniel C. ;

Jensen, Robert T. ;

de Herder, Wouter W. ;

Thakker, Rajesh V. ;

Caplin, Martyn ;

Delle Fave, Gianfranco ;

Kaltsas, Greg A. ;

Krenning, Eric P. ;

Moss, Steven F. ;

Nilsson, Ola ;

Rindi, Guido ;

Salazar, Ramon ;

Ruszniewski, Philippe ;

Sundin, Anders .

LANCET ONCOLOGY, 2008, 9 (01) :61-72

← 1 2 →